How long does a complete course of Enasidenib take?

Enasidenib is an oral drug mainly used to treat adult patients with acute myeloid leukemia (AML) with IDH2 mutations. As a targeted therapy drug, this drug interferes with the metabolic pathways of tumor cells by specifically inhibiting the enzyme activity of IDH2 mutations, thereby achieving anti-tumor effects. The duration of ensidipine treatment is usually determined based on the patient's clinical response and tolerability.

In clinical application, the recommended dose of ensidipine is 100 mg, taken orally once a day, and patients do not need to adjust the dosing time due to eating or not. The length of the treatment cycle usually depends on factors such as the patient's disease progression, drug tolerance, and treatment response. For patients who do not experience disease progression or unacceptable side effects, treatment for at least 6 months is generally recommended. This period of time helps to observe whether the patient has a clinical response to the drug, such as a reduction in the number of leukemia cells, relief of symptoms, etc.

Ensidipine treatment does not aim at the end of a fixed course of treatment, but rather determines whether to continue treatment based on the patient's clinical manifestations. If the patient does not experience significant disease progression within 6 months and does not experience unacceptable toxicity, treatment can continue. If the patient's condition progresses or serious side effects occur during treatment, the treatment may need to be adjusted or the drug discontinued.

It is worth noting that ensidipine is a long-term drug treatment, and the length of the treatment cycle should be determined by the doctor based on the individual needs of the patient. In some cases, patients may need to take ensidipine long-term to control the disease until the condition is effectively controlled. Therefore, patients need to undergo regular hematology tests and other related medical evaluations during treatment to ensure the effectiveness and safety of the treatment.

Reference materials:https://www.idhifa.com/